Trade Cellectar Biosciences, Inc. - CLRB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.98 |
| Open | 2 |
| 1-Year Change | N/A |
| Day's Range | 1.81 - 2 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 1.84 | -0.16 | -8.00% | 2.00 | 2.01 | 1.81 |
| Nov 14, 2024 | 1.98 | -0.10 | -4.81% | 2.08 | 2.08 | 1.96 |
| Nov 13, 2024 | 2.07 | -0.06 | -2.82% | 2.13 | 2.15 | 2.03 |
| Nov 12, 2024 | 2.11 | 0.01 | 0.48% | 2.10 | 2.12 | 2.06 |
| Nov 11, 2024 | 2.10 | 0.00 | 0.00% | 2.10 | 2.17 | 2.06 |
| Nov 8, 2024 | 2.09 | -0.01 | -0.48% | 2.10 | 2.11 | 2.04 |
| Nov 7, 2024 | 2.09 | 0.07 | 3.47% | 2.02 | 2.13 | 1.98 |
| Nov 6, 2024 | 2.05 | 0.03 | 1.49% | 2.02 | 2.05 | 1.99 |
| Nov 5, 2024 | 2.00 | -0.02 | -0.99% | 2.02 | 2.03 | 1.98 |
| Nov 4, 2024 | 2.01 | 0.02 | 1.01% | 1.99 | 2.04 | 1.98 |
| Nov 1, 2024 | 2.00 | 0.01 | 0.50% | 1.99 | 2.03 | 1.99 |
| Oct 31, 2024 | 2.01 | 0.00 | 0.00% | 2.01 | 2.04 | 1.96 |
| Oct 30, 2024 | 2.02 | -0.02 | -0.98% | 2.04 | 2.05 | 2.02 |
| Oct 29, 2024 | 2.02 | 0.01 | 0.50% | 2.01 | 2.04 | 1.97 |
| Oct 28, 2024 | 2.02 | -0.03 | -1.46% | 2.05 | 2.06 | 2.01 |
| Oct 25, 2024 | 2.00 | -0.04 | -1.96% | 2.04 | 2.09 | 1.99 |
| Oct 24, 2024 | 2.07 | 0.05 | 2.48% | 2.02 | 2.08 | 2.02 |
| Oct 23, 2024 | 2.01 | -0.05 | -2.43% | 2.06 | 2.12 | 2.01 |
| Oct 22, 2024 | 2.09 | 0.00 | 0.00% | 2.09 | 2.09 | 2.05 |
| Oct 21, 2024 | 2.08 | -0.01 | -0.48% | 2.09 | 2.11 | 2.06 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cellectar Biosciences, Inc. Company profile
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.
Equity composition
Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.
| Industry: | Pharmaceuticals (NEC) |
100 Campus Drive
FLORHAM PARK
NEW JERSEY 07932
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com